Revance price target raised to $39 from $34 at Mizuho
RVNC Mizuho analyst Difei Yang raised her price target for Revance Therapeutics to $39 from $34 after conducting an analysis of Teoxane's family of dermal fillers, specifically looking at market trends in the U.S. and patient reviews of the product in Europe.
Based on the analysis, the analyst is incrementally positive on her thesis that the combination of DAXI and RHA has created a "premium, longer-lasting" facial aesthetics portfolio that should benefit from a growing end market. Yang reiterates a Buy rating on Revance shares.
Market Data 
Markets 
AI
